4.5 Article

Aleglitazar, a balanced PPAR alpha/gamma agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Chemistry, Medicinal

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Agnes Benardeau et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)

Article Cardiac & Cardiovascular Systems

Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease

Koichi Sugamura et al.

CIRCULATION JOURNAL (2008)

Article Endocrinology & Metabolism

Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk

Thomas Forst et al.

DIABETES & VASCULAR DISEASE RESEARCH (2008)

Article Medicine, General & Internal

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Medicine, General & Internal

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial

Theodore Mazzone et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)

Article Cardiac & Cardiovascular Systems

Comparative safety of Atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients

C Newman et al.

AMERICAN JOURNAL OF CARDIOLOGY (2006)

Article Pharmacology & Pharmacy

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

JS Wang et al.

DRUG METABOLISM AND DISPOSITION (2002)